These discoveries led Negulescu and colleagues to develop VX-770 (later named ivacaftor), which rescues CF airway epithelial cell function in vitro by potentiating the activity of mutant CFTR-G551D (18). The gene discussed is CFTR; the disease is cystic fibrosis.